Acquisition Closed October 5, 2026
Theravance Biopharma, Inc. acquisition by Zymeworks Inc. (closed): stock options and RSUs
Completed: SEC filings show this deal closed by October 5, 2026. Zymeworks bought Theravance Biopharma for $17.00 per share in cash plus one contingent value right (CVR) per share.
- Buyer
- Zymeworks Inc.
- What holders receive
- $17.00 per share in cash plus a contingent value right (CVR)
- Agreement signed
- June 28, 2026
- Shareholder vote
- —
- Expected closing
- in the second half of 2026
- Closed
- October 5, 2026
How equity awards are treated
| Stock options | cashed out |
|---|---|
| Unvested RSUs | converted, keep vesting on original schedule (likely) |
| Performance awards (PSUs) | mentioned; terms vary |
Estimate your payout at $17.00 per share
Options pay the spread between the deal price and the exercise price; options priced at or above $17.00 usually pay nothing. Whether unvested awards pay now or later depends on the treatment above. Before taxes.
What this means for your taxes
- Shares you own outright are sold for cash at closing. That is a taxable sale: the gain over your cost basis is a capital gain, long-term if you have held the shares more than a year at closing. For shares from vested RSUs, your basis is generally the value already taxed at vesting (it was on your W-2).
- Options and RSUs paid in cash run through payroll as wages: income tax plus Social Security and Medicare. Employers usually withhold federal income tax at a flat 22%, or 37% on supplemental wages above $1 million in the calendar year (IRS Publication 15). If your top bracket is higher than 22%, withholding can fall short and you may owe more when you file; an estimated payment avoids a surprise.
- Incentive stock options that are cancelled for cash generally do not get ISO treatment: the payment is taxed like wages, the same as non-qualified options.
- ESPP shares sold in the deal within 2 years of the offering date or 1 year of purchase are a disqualifying disposition: part of the gain is taxed as ordinary income.
- Timing: expected closing is in the second half of 2026. If it could fall either side of December 31, the payout lands in a different tax year, which can matter for estimated payments and for bunching deductions.
General rules, not advice for your situation. Your award agreement and the merger agreement control. Full guide: stock options and RSUs in an acquisition →
Source
From the company's SEC filing: DEFM14A (accession 0001104659-26-099364). Last checked against the filing on November 19, 2026. Found an error? Corrections are made the same day; see how we check.
Questions
What will Theravance Biopharma, Inc. shareholders receive?
Under the merger agreement, holders receive $17.00 per share in cash plus a contingent value right (CVR).
What happens to Theravance Biopharma, Inc. stock options and RSUs?
Stock options: cashed out; Unvested RSUs: converted, keep vesting on original schedule (likely); Performance awards (PSUs): mentioned; terms vary
When will the deal close?
The filing expects closing in the second half of 2026. SEC filings show it closed by October 5, 2026.